CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer

Gelijkaardige items

• CCR 20(th) Anniversary Commentary: In the Beginning, There Was PS-341
  door: Teicher, Beverly A., et al.
  Gepubliceerd in: (2015)
• CCR 20(th) Anniversary Commentary: Simpson’s Paradox and Neoadjuvant Trials
  door: Carey, Lisa A.
  Gepubliceerd in: (2015)
• CCR 20(th) Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer
  door: Rahman, Mohammad Aminur, et al.
  Gepubliceerd in: (2015)
• Differential bortezomib sensitivity in head and neck cancer lines corresponds to proteasome, NF-κB and AP-1 related mechanisms
  door: Chen, Zhong, et al.
  Gepubliceerd in: (2008)
• CCR 20(th) Anniversary Commentary: Stayin’ Alive—Anti-apoptotic Proteins and Breast Cancer
  door: Yee, Douglas
  Gepubliceerd in: (2015)